ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
39 announcements with these filters
Fredun Pharmaceuticals reported FY26 revenue of ₹639.12 Crore, marking a 40% YoY jump. EBITDA surged 72% while PAT rose ~60% to ₹33.21 Crore.
Fredun Pharmaceuticals Ltd reported revenue from operations of ₹210.4 Cr (+27.2% YoY) and net profit of ₹10.8 Cr (+80.0% YoY) for Q4 FY26.
Fredun Pharmaceuticals approved FY2026 audited financial results and recommended a 7% final dividend. The board also proposed a 2:1 bonus share issue and increased authorized capital.
Fredun Pharmaceuticals announced a new 40,000 sq. ft. manufacturing facility in Palghar, Maharashtra, its fifth unit. The plant, expected to be operational by October 2026, will support veterinary and nutraceutical production. A further 50,000 sq. ft. expansion is also planned, strengthening the company's manufacturing footprint and scalability to meet domestic and international demand.
Fredun Pharmaceuticals Ltd (BSE: 539730) confirmed it does not qualify as a 'Large Corporate' under SEBI debt-raising norms for the 2026 financial year. The company reported outstanding borrowings of ₹216.43 Crore as of March 31. This routine regulatory disclosure provides transparency regarding the company's borrowing framework and debt market compliance status.
Fredun Pharmaceuticals Ltd promoters Fredun Nariman Medhora and others acquired 40,000 equity shares through the conversion of warrants on April 09, 2026. This conversion increases the total paid-up capital to 5,51,26,900 shares. The promoter group's voting rights increased from 44.17% to 44.57% following the allotment.
Fredun Pharmaceuticals Ltd allotted 40,000 equity shares to Director Daulat Nariman Medhora following the conversion of warrants. The transaction is valued at ₹5.0 Crore. This allotment increases the director's shareholding from 25.78% to 26.32%.
Fredun Pharmaceuticals Ltd allotted 40,000 equity shares to promoter Mrs. Daulat Nariman Medhora following the conversion of warrants. The transaction involved a balance payment of ₹3.75 Crore at an issue price of ₹1250 per share. This conversion completes the warrant exercise, resulting in nil warrants outstanding for this allottee.
Fredun Pharmaceuticals Ltd submitted its quarterly compliance certificate under Regulation 74(5) for the period ended March 31, 2026. The report confirms that 1,000 shares belonging to Nikhil Vora and Sheela Vora were dematerialised during the quarter. This is a routine regulatory filing with no material impact on business operations.